Axial involvement is present in approximately 25% of patients with PsA, with enthesitis, inflammatory bowel disease, and ...
10d
First for Women on MSNLa La Anthony on Her Plaque Psoriasis: ‘It Doesn't Have To Hold You Back'Since revealing her plaque psoriasis diagnosis in 2015, La La Anthony has become a powerful voice for those living with the ...
Between 45-56% of people living with psoriasis may experience these symptoms affecting the scalp, hairline, forehead, back of the neck and around the ears. Treatment includes use of over-the ...
Opens in a new tab or window Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the ...
Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...
Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...
Opens in a new tab or window Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an idea of how much the field has changed ...
Bristol Myers Squibb has released new 5-year results from the long-term trial evaluating Sotyktu for the treatment of adults ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results